Amlodipine/candesartan cilexetil

Drug Profile

Amlodipine/candesartan cilexetil

Alternative Names: Amlodipine besylate/candesartan cilexetil - Takeda; Candesartan cilexetil/amlodipine; TCV-116/amlodipine besilate; TCV-116CCB; Unisia

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Takeda
  • Class Antihypertensives; Benzimidazoles; Biphenyl compounds; Dihydropyridines; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 22 Dec 2016 Chemical structure information added
  • 17 Nov 2016 Takeda plans a phase III trial for Essential hypertension in China (PO) (NCT02969265)
  • 22 Jun 2015 Launched for Hypertension in Philippines (PO) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top